Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer

Summary Background Previous study indicated that an optional anti-cancer drug for the treatment of small-cell lung cancer (SCLC) is amrubicin. However, no prospective studies have evaluated amrubicin in chemo-naive elderly or poor-risk patients with SCLC. Therefore, this study aimed to evaluate the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2017-10, Vol.35 (5), p.642-648
Hauptverfasser:	Igawa, Satoshi, Otani, Sakiko, Ryuge, Shinichiro, Fukui, Tomoya, Nakahara, Yoshiro, Hiyoshi, Yasuhiro, Ishihara, Mikiko, Kusuhara, Seiichiro, Harada, Shinya, Mitsufuji, Hisashi, Kubota, Masaru, Sasaki, Jiichiro, Masuda, Noriyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Chemotherapy Confidence intervals Geriatrics Health risks Lung cancer Lung diseases Medicine Medicine & Public Health Neutropenia Older people Oncology Patients Pharmacology/Toxicology Phase II Studies Quality Risk Small cell lung carcinoma Studies Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!